741403
Last Update Posted: 2016-12-29
Recruiting has ended
All Genders accepted | 18 Years + |
39 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
A Open Label Phase I/II Clinical Trial to Evaluate CPI-613 in Patients With Advanced Malignancies
An open label, dose-escalation study to evaluate safety, tolerability, maximum tolerated dose (MTD), efficacy, and pharmacokinetics (PKs) of CPI-613 given twice weekly for three consecutive weeks in cancer patients
The objectives of this study are:
- To determine the safety and MTD of CPI-613 when administered 2x weekly for 3 consecutive weeks.
- To determine pharmacokinetics of CPI-613 following intravenous (IV) administration.
- To observe the anti-tumor effects of CPI-613, if any occur.
Eligibility
Relevant conditions:
Advanced Cancer
Metastatic Cancer
Lymphoma
Solid Tumors
Advanced Malignancies
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the study if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov